A review of the Augustine blood group system.
AUG
Amino acid sequence
Gene locus
HDN
Immunity mechanisms
Nucleoside transport
Oncology drug regulation
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
received:
18
01
2024
accepted:
13
05
2024
revised:
05
05
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Augustine is a newly identified blood group system comprising four antigens, one of which is the high-frequency antigen At
Identifiants
pubmed: 38767828
doi: 10.1007/s12185-024-03791-3
pii: 10.1007/s12185-024-03791-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Scientific Research Project of Hunan Provincial Health Commission
ID : 202211003190
Informations de copyright
© 2024. Japanese Society of Hematology.
Références
Baloch K, Chen L, et al. Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Antivir Chem Chemother. 2017;25(1):2–10.
doi: 10.1177/2040206616686894
pubmed: 28417642
pmcid: 5890492
Giovannetti E, Leon LG, et al. A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1. Nucleosides Nucleotides Nucleic Acids. 2016;35(10–12):643–51.
doi: 10.1080/15257770.2016.1149193
pubmed: 27906635
Zafar M, Naydenova Z, et al. Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1 (hENT1). Nucleosides Nucleotides Nucleic Acids. 2016;35(10–12):631–42.
doi: 10.1080/15257770.2016.1200074
pubmed: 27906634
Wu L, Shi W, et al. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. J Transl Med. 2016;14(1):66.
doi: 10.1186/s12967-016-0817-9
pubmed: 26944860
pmcid: 4779250
Yamada R, Mizuno S, et al. Human equilibrative nucleoside transporter 1 expression in endoscopic ultrasonography-guided fine-needle aspiration biopsy samples is a strong predictor of clinical response and survival in the patients with pancreatic ductal adenocarcinoma undergoing gemcitabine-based chemoradiotherapy. Pancreas. 2016;45(5):761–71.
doi: 10.1097/MPA.0000000000000597
pubmed: 26784908
pmcid: 4839740
Cass CE, Paterson AR. Mediated transport of nucleosides in human erythrocytes. Accelerative exchange diffusion of uridine and thymidine and specificity toward pyrimidine nucleosides as permeants. J Biol Chem. 1972;247(10):3314–20.
doi: 10.1016/S0021-9258(19)45247-2
pubmed: 5027755
Kuttesch JF Jr, Robins MJ, et al. Renal transport of 2’-deoxytubercidin in mice. Biochem Pharmacol. 1982;31(21):3387–94.
doi: 10.1016/0006-2952(82)90616-5
pubmed: 6216893
Belt JA, Welch AD. Transport of uridine and 6-azauridine in human lymphoblastoid cells Specificity for the uncharged 6-azauridine molecule. Mol Pharmacol. 1983;23(1):153–8.
pubmed: 6191189
Daniels G. The Augustine blood group system, 48 years in the making. Immunohematology. 2016;32:100–3.
doi: 10.21307/immunohematology-2019-053
pubmed: 27834482
Damaraju VL, Weber D, et al. Selective inhibition of human equilibrative and concentrative nucleoside transporters by BCR-ABL Kinase Inhibitors: identification of key hENT1 amino acid residues for interaction with BCR-ABL kinase inhibitorS. J Biol Chem. 2016;291(36):18809–17.
doi: 10.1074/jbc.M116.741074
pubmed: 27432881
pmcid: 5009255
Panigrahi R, Dash S. ENT1 and treatment of viral diseases. Oncotarget. 2015;6(32):32281–2.
doi: 10.18632/oncotarget.5859
pubmed: 26431496
pmcid: 4741678
Aseervatham J, Tran L, et al. The role of flexible loops in folding, trafficking and activity of equilibrative nucleoside transporters. PLoS ONE. 2015;10(9):e0136779.
doi: 10.1371/journal.pone.0136779
pubmed: 26406980
pmcid: 4583308
Wan H, Zhu J, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33(1):90.
doi: 10.1186/s13046-014-0090-9
pubmed: 25398670
pmcid: 4234887
Tavano F, Fontana A, et al. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. Pancreatology. 2014;12(1):1–11.
Ormanns S, Heinemann V, et al. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur J Cancer. 2014;50(11):1891–9.
doi: 10.1016/j.ejca.2014.04.023
pubmed: 24857044
Zhu Y, Qi M, et al. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Genet Test Mol Biomark. 2014;18(5):306–12.
doi: 10.1089/gtmb.2013.0419
Furihata T, Mizuguchi M, et al. Identification of primary equilibrative nucleoside transporter 1 mRNA isoforms resulting from alternative promoter usage in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):325–32.
doi: 10.2133/dmpk.DMPK-13-RG-135
pubmed: 24522200
Liu ZQ, Liu ZQ, et al. Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS ONE. 2014;9(1):e87103.
doi: 10.1371/journal.pone.0087103
pubmed: 24475233
pmcid: 3903621
Mohelnikova-Duchonova B, Melichar B. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? Pancreatology. 2013;13(6):558–63.
doi: 10.1016/j.pan.2013.09.005
pubmed: 24280569
Wei CH, Gorgan TR, et al. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas. 2013;42(8):1303–10.
doi: 10.1097/MPA.0b013e3182a23ae4
pubmed: 24152955
Suzuki Y, Homma M, et al. Impact of solute carrier family 29 member 1 (SLC29A1) single nucleotide polymorphisms on mRNA expression in peripheral blood mononuclear cells. Biol Pharm Bull. 2013;36(1):144–6.
doi: 10.1248/bpb.b12-00809
pubmed: 23095574
Daniels G. Augustine blood group system and equilibrative nucleoside transporter 1. Transfus Med Hemother. 2022;49:25–9.
doi: 10.1159/000520596
pubmed: 35221865
Millard GM, McGowan EC, et al. A proposed new low-frequency antigen in the Augustine blood group system associated with a severe case of hemolytic disease of the fetus and newborn. Transfusion. 2018;58:1320–2.
doi: 10.1111/trf.14562
pubmed: 29504136
Yao SY, Ng AM, et al. Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem. 2011;286(37):32552–62.
doi: 10.1074/jbc.M111.236117
pubmed: 21795683
pmcid: 3173155
Guillén-Gómez E, Pinilla-Macua I, et al. New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells. J Cell Physiol. 2012;227(4):1521–8.
doi: 10.1002/jcp.22869
pubmed: 21678404
Xu Z, Li SZ. Research progress of erythrocyte blood group antigen. Clin Hematol Transfus Testing. 2016;29(4):345–50.